Integra LifeSciences (IART) Financials

$13.12 +0.82 (+6.67%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$13.10 -0.02 (-0.16%)

As of 04:00 AM Eastern

Annual Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-6.94	68	181	169	134	50	61	65	75	-3.52	34
Consolidated Net Income / (Loss)	-6.94	68	181	169	134	50	61	65	75	-3.52	34
Net Income / (Loss) Continuing Operations	-6.94	68	181	169	134	50	61	65	75	6.85	36
Total Pre-Tax Income	-18	81	214	215	94	60	57	11	90	61	46
Total Operating Income	28	112	239	197	151	94	111	45	115	80	68
Total Gross Profit	882	885	970	945	851	953	901	753	643	556	494
Total Revenue	1,611	1,542	1,558	1,542	1,372	1,518	1,472	1,188	992	883	797
Operating Revenue	1,611	1,542	1,558	1,542	1,372	1,518	1,472	1,188	992	883	797
Total Cost of Revenue	728	657	587	598	521	565	571	436	349	327	303
Operating Cost of Revenue	728	657	587	598	521	565	571	436	349	327	303
Total Operating Expenses	854	773	731	747	700	859	790	708	528	477	426
Selling, General & Admin Expense	717	657	616	637	595	688	691	624	456	416	376
Research & Development Expense	115	104	101	93	77	144	78	63	58	51	44
Amortization Expense	21	12	14	17	28	27	21	20	14	9.95	6.81
Total Other Income / (Expense), net	-47	-30	-25	17	-58	-34	-54	-33	-25	-19	-22
Interest Expense	71	51	50	50	72	54	65	35	26	24	22
Interest & Investment Income	20	17	12	6.74	9.30	11	2.80	0.26	0.02	0.03	0.17
Other Income / (Expense), net	3.94	3.72	13	61	4.43	9.52	8.29	1.35	0.85	4.59	-0.49
Income Tax Expense	-11	13	33	46	-40	9.90	-3.40	-53	16	54	9.27
Basic Earnings per Share	($0.09)	$0.85	$2.18	$2.00	$1.58	$0.59	$0.73	$0.84	$1.00	($0.05)	$0.52
Weighted Average Basic Shares Outstanding	77.01M	80.09M	83.00M	84.70M	84.65M	85.64M	82.86M	76.90M	74.39M	68.99M	64.86M
Diluted Earnings per Share	($0.09)	$0.84	$2.16	$1.98	$1.57	$0.58	$0.72	$0.82	$0.94	($0.05)	$0.52
Weighted Average Diluted Shares Outstanding	77.01M	80.34M	83.52M	85.49M	85.23M	86.49M	84.00M	79.12M	79.19M	71.35M	65.92M
Weighted Average Basic & Diluted Shares Outstanding	77.22M	78.22M	81.64M	83.24M	84.37M	84.44M	83.30M	77.10M	74.60M	70.40M	32.40M

This table shows Integra LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-25	19	-11	-12	-3.28	20	19	4.18	24	53	50
Consolidated Net Income / (Loss)	-25	19	-11	-12	-3.28	20	19	4.18	24	53	50
Net Income / (Loss) Continuing Operations	-25	19	-11	-12	-3.28	20	19	4.18	24	53	50
Total Pre-Tax Income	-30	23	-20	-15	-5.23	29	19	3.82	30	64	59
Total Operating Income	-15	36	-8.15	-3.03	3.96	36	27	13	36	68	65
Total Gross Profit	194	249	200	226	207	226	218	207	233	250	237
Total Revenue	383	443	381	418	369	397	382	381	381	398	385
Operating Revenue	383	443	381	418	369	397	382	381	381	398	385
Total Cost of Revenue	188	194	181	192	162	171	164	174	148	148	148
Operating Cost of Revenue	188	194	181	192	162	171	164	174	148	148	148
Total Operating Expenses	210	213	208	229	203	190	192	195	196	182	172
Selling, General & Admin Expense	181	179	177	195	166	163	162	165	167	152	144
Research & Development Expense	25	31	27	30	27	24	27	27	27	27	25
Amortization Expense	3.70	3.72	3.76	3.71	10	3.03	3.21	3.03	3.11	3.54	3.14
Total Other Income / (Expense), net	-15	-13	-12	-12	-9.19	-7.19	-7.98	-8.68	-6.60	-3.63	-6.25
Interest Expense	19	19	19	19	14	14	13	12	12	13	13
Interest & Investment Income	4.42	4.89	5.05	5.06	5.04	4.55	4.61	3.94	4.11	5.31	3.26
Other Income / (Expense), net	-0.14	1.01	2.11	1.44	-0.61	2.01	0.47	-0.16	1.39	3.95	3.29
Income Tax Expense	-4.74	3.11	-9.67	-2.78	-1.95	9.02	-0.89	-0.36	5.55	11	8.88
Basic Earnings per Share	($0.33)	$0.25	($0.14)	($0.16)	($0.04)	$0.26	$0.24	$0.05	$0.30	$0.65	$0.60
Weighted Average Basic Shares Outstanding	76.46M	77.01M	76.45M	77.41M	77.74M	80.09M	79.69M	80.97M	81.87M	83.00M	83.04M
Diluted Earnings per Share	($0.33)	$0.25	($0.14)	($0.16)	($0.04)	$0.26	$0.24	$0.05	$0.29	$0.63	$0.60
Weighted Average Diluted Shares Outstanding	76.46M	77.01M	76.45M	77.41M	77.74M	80.34M	79.81M	81.15M	82.32M	83.52M	83.40M
Weighted Average Basic & Diluted Shares Outstanding	77.71M	77.22M	77.16M	77.58M	78.80M	78.22M	78.18M	81.40M	81.90M	81.64M	83.52M

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	-30	-180	-57	43	271	60	-31	73	54	-24	-49
Net Cash From Operating Activities	129	140	264	312	204	231	200	115	116	105	84
Net Cash From Continuing Operating Activities	129	140	264	312	204	231	200	115	116	117	63
Net Income / (Loss) Continuing Operations	-6.94	68	181	169	134	50	61	65	75	6.85	36
Consolidated Net Income / (Loss)	-6.94	68	181	169	134	50	61	65	75	-3.52	34
Depreciation Expense	141	124	118	120	116	109	111	89	73	59	46
Amortization Expense	5.59	6.16	6.85	-	12	5.39	6.27	2.72	2.53	2.26	2.57
Non-Cash Adjustments To Reconcile Net Income	47	23	23	10	46	99	27	31	-16	60	23
Changes in Operating Assets and Liabilities, net	-58	-81	-64	13	-105	-32	-5.22	-73	-18	-11	-45
Net Cash From Investing Activities	-391	-94	-59	-161	-68	-163	-50	-1,221	-43	-372	-363
Net Cash From Continuing Investing Activities	-391	-94	-59	-161	-68	-163	-50	-1,221	-43	-365	-360
Purchase of Property, Plant & Equipment	-104	-67	-42	-48	-39	-70	-78	-44	-47	-33	-38
Acquisitions	-288	0.00	-56	-304	-25	-96	0.00	-1,242	-	-329	-321
Purchase of Investments	-53	-27	4.91	0.00	-7.84	1.58	0.00	-	-	-	-
Sale of Property, Plant & Equipment	0.00	0.00	11	0.00	3.66	0.04	0.42	0.29	0.32	1.44	0.00
Divestitures	0.00	0.00	24	190	0.00	0.00	27	46	0.00	0.00	-
Sale and/or Maturity of Investments	55	0.00	0.00	0.08	-	0.75	0.91	17	0.00	0.00	-
Net Cash From Financing Activities	238	-230	-252	-98	122	-8.77	-181	1,169	-15	248	239
Net Cash From Continuing Financing Activities	238	-230	-252	-98	122	-8.77	-181	1,169	-15	295	239
Repayment of Debt	-187	-118	-149	-126	-465	-246	-665	-136	-701	-470	-199
Repurchase of Common Equity	-52	-275	-125	0.00	-100	0.00	0.00	-	-	-	-
Issuance of Debt	487	165	41	26	747	237	171	1,307	680	545	425
Other Financing Activities, net	-9.04	-1.55	-19	2.02	-104	0.43	-37	-2.01	5.63	0.72	12
Other Net Changes in Cash	-6.46	3.89	-11	-	-	0.07	-	11	-	-	-

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-7.27	31	-0.08	-377	316	2.67	-35	1.83	-149	-55	65
Net Cash From Operating Activities	-11	51	22	40	16	59	27	28	26	85	68
Net Cash From Continuing Operating Activities	-11	51	22	40	16	59	27	28	26	85	68
Net Income / (Loss) Continuing Operations	-25	19	-11	-12	-3.28	20	19	4.18	24	53	50
Consolidated Net Income / (Loss)	-25	19	-11	-12	-3.28	20	19	4.18	24	53	50
Depreciation Expense	37	38	36	37	31	31	31	31	31	29	29
Amortization Expense	1.39	1.40	1.34	1.46	1.40	1.43	1.42	1.42	1.89	1.70	1.75
Non-Cash Adjustments To Reconcile Net Income	2.11	17	3.66	14	13	6.64	5.93	5.68	4.86	-2.22	10
Changes in Operating Assets and Liabilities, net	-27	-24	-7.77	0.44	-26	-0.15	-31	-14	-36	3.41	-23
Net Cash From Investing Activities	-36	-4.25	-10	-322	-54	-57	-7.70	-16	-14	-55	15
Net Cash From Continuing Investing Activities	-36	-4.25	-10	-322	-54	-57	-7.70	-16	-14	-55	15
Purchase of Property, Plant & Equipment	-29	-30	-30	-30	-15	-25	-13	-16	-14	-14	-9.16
Purchase of Investments	-7.00	-4.13	-	-10	-39	-33	5.38	-	0.00	-	-
Net Cash From Financing Activities	35	-7.15	-20	-94	359	-6.89	-50	-11	-163	-98	-7.64
Net Cash From Continuing Financing Activities	35	-7.15	-20	-94	359	-6.89	-50	-11	-163	-98	-7.64
Repayment of Debt	-15	-40	-42	-91	-15	-25	-57	-17	-20	-108	-18
Issuance of Debt	54	35	22	59	371	18	132	5.00	10	6.50	11
Other Financing Activities, net	-3.78	-0.14	-0.17	-12	3.28	-0.09	0.44	1.01	-2.91	3.60	-1.14
Other Net Changes in Cash	4.53	-8.12	7.75	-1.13	-4.96	8.04	-4.87	-0.21	0.94	12	-

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	4,037	3,782	3,890	3,782	3,615	3,303	3,108	3,211	1,808	1,774	1,587
Total Current Assets	1,082	1,058	1,161	1,154	1,237	858	775	822	495	438	529
Cash & Equivalents	246	276	457	513	470	199	139	175	102	48	72
Short-Term Investments	27	33	0.00	-	-	-	-	-	-	-	-
Accounts Receivable	272	259	263	232	226	275	266	252	148	132	110
Inventories, net	429	390	325	317	310	316	280	296	217	211	189
Prepaid Expenses	77	67	86	91	69	68	90	99	28	43	28
Other Current Assets	30	33	31	-	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	406	340	311	312	288	337	300	269	222	205	194
Total Noncurrent Assets	2,550	2,384	2,417	2,317	2,090	2,108	2,033	2,120	1,090	1,131	864
Goodwill	1,097	1,055	1,039	1,013	932	954	926	938	511	512	363
Intangible Assets	1,208	1,068	1,127	1,146	989	1,032	1,079	1,160	561	604	413
Noncurrent Deferred & Refundable Income Taxes	35	46	46	57	74	13	6.81	6.25	6.94	6.93	4.47
Other Noncurrent Operating Assets	211	214	205	101	95	109	20	16	12	7.49	10
Total Liabilities & Shareholders' Equity	4,037	3,782	3,890	3,782	3,615	3,303	3,108	3,211	1,808	1,774	1,587
Total Liabilities	2,492	2,194	2,085	2,098	2,100	1,887	1,732	2,249	968	1,023	883
Total Current Liabilities	922	307	321	340	401	331	263	349	124	139	126
Short-Term Debt	607	15	38	45	146	45	23	83	0.00	14	3.75
Accounts Payable	83	92	102	62	55	113	76	94	29	35	29
Accrued Expenses	122	101	80	120	94	77	85	88	35	39	40
Current Employee Benefit Liabilities	86	75	79	93	76	79	76	73	53	45	35
Other Current Liabilities	25	24	22	20	13	12	-	-	-	-	-
Total Noncurrent Liabilities	1,570	1,887	1,764	1,758	1,699	1,555	1,470	1,900	845	884	757
Long-Term Debt	1,196	1,485	1,405	1,501	1,408	1,303	1,332	1,781	665	700	626
Capital Lease Obligations	167	167	157	90	-	-	-	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	61	35	63	46	16	37	58	65	149	155	100
Other Noncurrent Operating Liabilities	146	200	139	120	275	216	80	54	31	29	28
Total Equity & Noncontrolling Interests	1,545	1,588	1,804	1,685	1,515	1,417	1,376	962	840	751	704
Total Preferred & Common Equity	1,545	1,588	1,804	1,685	1,515	1,417	1,376	962	840	751	704
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,545	1,588	1,804	1,685	1,515	1,417	1,376	962	840	751	704
Common Stock	1,324	1,303	1,278	1,266	1,292	1,215	1,193	823	799	1,021	780
Retained Earnings	940	947	879	699	532	399	348	285	220	146	315
Treasury Stock	-691	-647	-363	-234	-235	-120	-121	-122	-123	-367	-367
Accumulated Other Comprehensive Income / (Loss)	-28	-15	10	-45	-74	-76	-45	-24	-57	-48	-23

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	4,053	4,066	4,074	4,078	3,739	3,778	3,742	3,807
Total Current Assets	1,107	1,100	1,112	1,416	1,027	1,051	1,029	1,196
Cash & Equivalents	239	215	215	592	274	309	307	512
Short-Term Investments	34	62	82	71	-	-	-	-
Accounts Receivable	252	248	271	241	256	259	254	248
Inventories, net	445	437	422	403	366	354	351	311
Prepaid Expenses	104	86	94	73	131	129	117	123
Other Current Assets	32	50	29	35	-	-	-	1.83
Plant, Property, & Equipment, net	423	391	374	345	319	318	315	301
Total Noncurrent Assets	2,523	2,575	2,589	2,317	2,393	2,409	2,398	2,310
Goodwill	1,105	1,117	1,105	1,040	1,036	1,043	1,042	978
Intangible Assets	1,188	1,210	1,220	1,023	1,067	1,094	1,109	1,054
Noncurrent Deferred & Refundable Income Taxes	38	49	46	34	56	56	45	52
Other Noncurrent Operating Assets	192	200	218	220	235	216	203	226
Total Liabilities & Shareholders' Equity	4,053	4,066	4,074	4,078	3,739	3,778	3,742	3,807
Total Liabilities	2,529	2,544	2,540	2,480	2,160	2,094	2,067	2,083
Total Current Liabilities	918	913	328	302	356	377	282	304
Short-Term Debt	613	602	24	19	85	96	0.00	56
Accounts Payable	91	78	107	94	94	100	113	81
Accrued Expenses	137	132	102	112	90	95	93	79
Current Employee Benefit Liabilities	52	76	70	53	64	65	54	69
Other Current Liabilities	25	15	25	24	23	23	23	13
Total Noncurrent Liabilities	1,610	1,632	2,212	2,178	1,804	1,717	1,785	1,778
Long-Term Debt	1,231	1,205	1,801	1,837	1,420	1,333	1,440	1,487
Capital Lease Obligations	161	-	170	170	168	160	157	-
Noncurrent Deferred & Payable Income Tax Liabilities	58	69	87	31	74	71	62	70
Other Noncurrent Operating Liabilities	160	358	155	140	142	153	127	221
Total Equity & Noncontrolling Interests	1,524	1,522	1,534	1,598	1,579	1,683	1,675	1,724
Total Preferred & Common Equity	1,524	1,522	1,534	1,598	1,579	1,683	1,675	1,724
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,524	1,522	1,534	1,598	1,579	1,683	1,675	1,724
Common Stock	1,324	1,318	1,302	1,311	1,263	1,285	1,246	1,269
Retained Earnings	915	920	931	944	927	908	903	826
Treasury Stock	-690	-692	-681	-646	-613	-514	-482	-363
Accumulated Other Comprehensive Income / (Loss)	-24	-25	-19	-11	1.75	4.83	7.07	-7.44

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.47%	-1.03%	0.99%	12.43%	-9.60%	3.06%	23.92%	19.77%	12.39%	10.80%	14.33%
EBITDA Growth	-26.98%	-34.99%	-0.39%	33.20%	30.15%	-7.68%	71.45%	-27.99%	31.71%	24.86%	73.97%
EBIT Growth	-71.92%	-54.19%	-2.62%	65.81%	50.85%	-13.42%	158.48%	-60.28%	38.03%	24.95%	100.62%
NOPAT Growth	-78.66%	-53.79%	29.83%	-28.32%	176.73%	-33.39%	-53.86%	167.83%	958.51%	-83.37%	30.32%
Net Income Growth	-110.25%	-62.48%	6.79%	26.28%	166.71%	-17.43%	-6.09%	-13.17%	2,218.90%	-110.35%	261.41%
EPS Growth	-110.71%	-61.11%	9.09%	26.11%	170.69%	-19.44%	-12.20%	-12.77%	2,218.90%	-110.35%	261.41%
Operating Cash Flow Growth	-7.55%	-47.08%	-15.35%	53.28%	-11.93%	15.90%	74.33%	-1.60%	11.02%	25.48%	56.88%
Free Cash Flow Firm Growth	-386.75%	58.00%	129.98%	-161.03%	222.20%	-41.70%	117.88%	-1,035.49%	135.50%	-162.76%	-356.94%
Invested Capital Growth	10.07%	-0.11%	5.01%	14.66%	-4.56%	-0.98%	-2.27%	89.03%	-0.79%	27.88%	17.91%
Revenue Q/Q Growth	2.91%	-0.06%	-0.48%	1.11%	-0.47%	0.78%	1.01%	10.50%	1.48%	11.13%	9.84%
EBITDA Q/Q Growth	2.96%	-11.72%	4.12%	1.63%	5.78%	0.63%	11.57%	-13.10%	9.58%	1.85%	-12.71%
EBIT Q/Q Growth	-4.23%	-22.64%	3.85%	3.35%	12.21%	1.14%	24.82%	-39.20%	16.43%	-3.82%	-33.50%
NOPAT Q/Q Growth	-1.46%	-24.94%	2.43%	-24.43%	130.64%	-17.25%	-50.58%	244.04%	17.19%	-43.89%	-37.89%
Net Income Q/Q Growth	-6.11%	-32.83%	4.37%	-21.88%	137.12%	-16.36%	-24.02%	33.12%	21.64%	-163.99%	11.09%
EPS Q/Q Growth	-12.50%	-30.58%	4.85%	-21.74%	134.33%	-17.14%	-23.40%	32.26%	21.64%	-163.99%	11.09%
Operating Cash Flow Q/Q Growth	-5.83%	-15.96%	6.46%	-3.40%	-4.19%	25.14%	18.48%	4.58%	-14.10%	0.75%	18.70%
Free Cash Flow Firm Q/Q Growth	-433.12%	197.97%	-58.35%	-73.87%	5.26%	21.95%	123.51%	-695.62%	82.82%	-52.85%	26.97%
Invested Capital Q/Q Growth	6.27%	-1.12%	6.99%	3.78%	2.77%	-1.54%	-0.20%	65.44%	-0.07%	2.41%	-5.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.77%	57.39%	62.29%	61.24%	62.03%	62.79%	61.19%	63.35%	64.81%	63.01%	61.98%
EBITDA Margin	11.10%	15.89%	24.18%	24.52%	20.70%	14.37%	16.05%	11.60%	19.29%	16.46%	14.61%
Operating Margin	1.76%	7.23%	15.34%	12.79%	11.03%	6.18%	7.54%	3.77%	11.63%	9.02%	8.52%
EBIT Margin	2.01%	7.48%	16.15%	16.75%	11.36%	6.81%	8.10%	3.88%	11.71%	9.54%	8.46%
Profit (Net Income) Margin	-0.43%	4.39%	11.59%	10.96%	9.76%	3.31%	4.13%	5.45%	7.52%	-0.40%	4.27%
Tax Burden Percent	38.08%	83.56%	84.41%	78.76%	143.17%	83.52%	105.92%	568.67%	82.48%	-5.80%	74.63%
Interest Burden Percent	-56.37%	70.35%	85.02%	83.10%	60.02%	58.19%	48.12%	24.67%	77.81%	72.08%	67.64%
Effective Tax Rate	0.00%	16.44%	15.59%	21.24%	-43.17%	16.48%	-5.92%	-468.67%	17.52%	88.71%	20.35%
Return on Invested Capital (ROIC)	0.64%	3.16%	7.01%	5.91%	8.64%	3.04%	4.49%	12.57%	6.76%	0.71%	5.29%
ROIC Less NNEP Spread (ROIC-NNEP)	-1.11%	1.13%	5.14%	7.25%	0.69%	0.66%	0.58%	-4.31%	3.40%	-1.64%	-0.67%
Return on Net Nonoperating Assets (RNNOA)	-1.09%	0.83%	3.34%	4.66%	0.49%	0.56%	0.72%	-5.38%	2.62%	-1.20%	-0.33%
Return on Equity (ROE)	-0.44%	3.99%	10.35%	10.57%	9.13%	3.60%	5.20%	7.19%	9.37%	-0.48%	4.96%
Cash Return on Invested Capital (CROIC)	-8.94%	3.27%	2.12%	-7.75%	13.31%	4.02%	6.78%	-49.03%	7.54%	-23.76%	-11.15%
Operating Return on Assets (OROA)	0.83%	3.00%	6.56%	6.98%	4.50%	3.22%	3.78%	1.84%	6.49%	5.01%	4.85%
Return on Assets (ROA)	-0.18%	1.77%	4.71%	4.57%	3.87%	1.57%	1.92%	2.58%	4.16%	-0.21%	2.45%
Return on Common Equity (ROCE)	-0.44%	3.99%	10.35%	10.57%	9.13%	3.60%	5.20%	7.19%	9.37%	-0.48%	4.96%
Return on Equity Simple (ROE_SIMPLE)	-0.45%	4.27%	10.01%	10.04%	8.84%	3.54%	4.42%	6.73%	8.88%	-0.47%	4.83%
Net Operating Profit after Tax (NOPAT)	20	93	202	155	217	78	118	255	95	8.99	54
NOPAT Margin	1.23%	6.05%	12.95%	10.07%	15.80%	5.16%	7.98%	21.44%	9.59%	1.02%	6.78%
Net Nonoperating Expense Percent (NNEP)	1.76%	2.03%	1.86%	-1.34%	7.95%	2.38%	3.91%	16.88%	3.36%	2.35%	5.96%
Return On Investment Capital (ROIC_SIMPLE)	0.57%	2.86%	5.92%	4.68%	7.06%	2.83%	4.31%	9.02%	6.32%	0.61%	4.05%
Cost of Revenue to Revenue	45.23%	42.61%	37.71%	38.76%	37.97%	37.21%	38.81%	36.65%	35.19%	36.99%	38.02%
SG&A Expenses to Revenue	44.52%	42.60%	39.57%	41.33%	43.34%	45.31%	46.91%	52.52%	45.93%	47.10%	47.14%
R&D to Revenue	7.16%	6.76%	6.50%	6.03%	5.64%	9.52%	5.30%	5.34%	5.86%	5.77%	5.47%
Operating Expenses to Revenue	53.00%	50.16%	46.95%	48.46%	51.00%	56.61%	53.65%	59.58%	53.19%	53.99%	53.46%
Earnings before Interest and Taxes (EBIT)	32	115	252	258	156	103	119	46	116	84	67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	179	245	377	378	284	218	236	138	191	145	116
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.13	2.14	2.60	3.37	3.61	3.53	2.79	3.90	3.82	3.34	2.52
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.09	2.21	3.01	3.68	3.99	3.30	2.61	3.16	3.23	2.84	2.23
Price to Earnings (P/E)	0.00	50.26	25.94	33.56	40.86	99.68	63.18	58.01	43.01	0.00	52.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	1.99%	3.86%	2.98%	2.45%	1.00%	1.58%	1.72%	2.32%	0.00%	1.91%
Enterprise Value to Invested Capital (EV/IC)	1.06	1.62	1.98	2.42	2.68	2.40	1.95	2.05	2.69	2.24	2.11
Enterprise Value to Revenue (EV/Rev)	2.14	3.09	3.74	4.41	4.78	4.05	3.43	4.58	3.80	3.59	2.93
Enterprise Value to EBITDA (EV/EBITDA)	19.27	19.44	15.47	17.97	23.09	28.21	21.40	39.51	19.70	21.81	20.08
Enterprise Value to EBIT (EV/EBIT)	106.52	41.32	23.16	26.31	42.07	59.58	42.39	117.99	32.45	37.65	34.68
Enterprise Value to NOPAT (EV/NOPAT)	173.30	51.10	28.89	43.76	30.25	78.58	43.01	21.37	39.63	352.61	43.23
Enterprise Value to Operating Cash Flow (EV/OCF)	26.64	34.02	22.03	21.76	32.16	26.59	25.33	47.54	32.39	30.22	27.96
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	49.36	95.42	0.00	19.64	59.40	28.46	0.00	35.49	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.27	1.05	0.89	0.97	1.03	0.95	0.98	1.94	0.79	0.95	0.89
Long-Term Debt to Equity	0.88	1.04	0.87	0.94	0.93	0.92	0.97	1.85	0.79	0.93	0.89
Financial Leverage	0.97	0.74	0.65	0.64	0.71	0.85	1.24	1.25	0.77	0.73	0.49
Leverage Ratio	2.50	2.26	2.20	2.31	2.36	2.30	2.70	2.79	2.25	2.31	2.03
Compound Leverage Factor	-1.41	1.59	1.87	1.92	1.42	1.34	1.30	0.69	1.75	1.66	1.37
Debt to Total Capital	56.04%	51.21%	47.01%	49.27%	50.65%	48.76%	49.60%	65.95%	44.20%	48.74%	47.21%
Short-Term Debt to Total Capital	17.27%	0.45%	1.12%	1.35%	4.76%	1.63%	0.82%	2.93%	0.00%	0.98%	0.28%
Long-Term Debt to Total Capital	38.77%	50.76%	45.89%	47.92%	45.88%	47.13%	48.78%	63.02%	44.20%	47.76%	46.93%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	43.96%	48.79%	52.99%	50.73%	49.35%	51.24%	50.40%	34.05%	55.80%	51.26%	52.79%
Debt to EBITDA	11.02	6.80	4.25	4.33	5.48	6.18	5.73	13.52	3.47	4.92	5.41
Net Debt to EBITDA	9.49	5.54	3.04	2.97	3.82	5.27	5.14	12.26	2.94	4.56	4.80
Long-Term Debt to EBITDA	7.62	6.74	4.15	4.21	4.96	5.97	5.64	12.92	3.47	4.82	5.38
Debt to NOPAT	99.06	17.88	7.94	10.54	7.17	17.21	11.52	7.32	6.99	79.50	11.66
Net Debt to NOPAT	85.30	14.56	5.67	7.23	5.00	14.67	10.34	6.63	5.92	73.69	10.33
Long-Term Debt to NOPAT	68.53	17.73	7.75	10.25	6.50	16.64	11.33	6.99	6.99	77.90	11.59
Altman Z-Score	1.22	2.03	2.54	2.77	2.57	2.51	2.29	1.72	3.17	2.44	2.43
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.17	3.45	3.62	3.39	3.09	2.59	2.95	2.36	4.01	3.15	4.20
Quick Ratio	0.59	1.85	2.24	2.19	1.73	1.43	1.54	1.22	2.02	1.30	1.45
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-277	96	61	-204	334	104	178	-994	106	-299	-114
Operating Cash Flow to CapEx	123.91%	209.31%	847.71%	650.63%	578.53%	333.00%	258.26%	265.09%	247.61%	327.92%	217.96%
Free Cash Flow to Firm to Interest Expense	-3.92	1.88	1.23	-4.04	4.66	1.92	2.75	-28.38	4.12	-12.72	-5.18
Operating Cash Flow to Interest Expense	1.83	2.72	5.33	6.20	2.85	4.29	3.09	3.27	4.51	4.46	3.80
Operating Cash Flow Less CapEx to Interest Expense	0.35	1.42	4.70	5.25	2.36	3.00	1.89	2.04	2.69	3.10	2.06
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.40	0.41	0.42	0.40	0.47	0.47	0.47	0.55	0.53	0.57
Accounts Receivable Turnover	6.06	5.90	6.29	6.75	5.48	5.61	5.69	5.94	7.08	7.28	6.97
Inventory Turnover	1.78	1.84	1.83	1.91	1.66	1.89	1.98	1.70	1.63	1.63	1.53
Fixed Asset Turnover	4.32	4.73	5.00	5.15	4.39	4.76	5.17	4.83	4.64	4.43	4.04
Accounts Payable Turnover	8.33	6.76	7.17	10.27	6.21	5.97	6.72	7.08	10.94	10.26	7.61
Days Sales Outstanding (DSO)	60.25	61.89	58.03	54.11	66.63	65.06	64.15	61.43	51.59	50.17	52.35
Days Inventory Outstanding (DIO)	205.11	198.44	199.47	191.57	219.41	192.75	184.16	215.22	224.12	223.87	238.59
Days Payable Outstanding (DPO)	43.80	54.02	50.94	35.55	58.76	61.13	54.29	51.55	33.37	35.57	47.96
Cash Conversion Cycle (CCC)	221.56	206.31	206.56	210.13	227.27	196.69	194.01	225.10	242.33	238.47	242.98
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,242	2,945	2,948	2,808	2,449	2,566	2,591	2,651	1,403	1,414	1,105
Invested Capital Turnover	0.52	0.52	0.54	0.59	0.55	0.59	0.56	0.59	0.70	0.70	0.78
Increase / (Decrease) in Invested Capital	297	-3.29	141	359	-117	-25	-60	1,249	-11	308	168
Enterprise Value (EV)	3,447	4,762	5,827	6,797	6,555	6,153	5,057	5,445	3,770	3,169	2,336
Market Capitalization	1,750	3,405	4,683	5,674	5,471	5,004	3,842	3,756	3,207	2,507	1,778
Book Value per Share	$20.03	$20.31	$21.60	$19.89	$17.98	$16.50	$16.15	$12.26	$22.46	$20.32	$21.48
Tangible Book Value per Share	($9.84)	($6.85)	($4.32)	($5.60)	($4.83)	($6.63)	($7.40)	($14.47)	($6.21)	($9.86)	($2.19)
Total Capital	3,515	3,254	3,405	3,321	3,069	2,765	2,730	2,826	1,505	1,466	1,334
Total Debt	1,970	1,666	1,601	1,637	1,554	1,348	1,354	1,864	665	714	630
Total Long-Term Debt	1,363	1,652	1,563	1,592	1,408	1,303	1,332	1,781	665	700	626
Net Debt	1,696	1,357	1,144	1,123	1,084	1,149	1,215	1,689	563	662	558
Capital Expenditures (CapEx)	104	67	31	48	35	70	77	43	47	32	38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	493	456	422	345	512	373	396	381	270	262	335
Debt-free Net Working Capital (DFNWC)	767	766	879	859	982	572	535	556	372	314	407
Net Working Capital (NWC)	160	751	841	814	836	527	513	473	372	299	403
Net Nonoperating Expense (NNE)	27	25	21	-14	83	28	57	190	21	13	20
Net Nonoperating Obligations (NNO)	1,696	1,357	1,144	1,123	934	1,149	1,215	1,689	563	662	401
Total Depreciation and Amortization (D&A)	146	130	125	120	128	115	117	92	75	61	49
Debt-free, Cash-free Net Working Capital to Revenue	30.62%	29.61%	27.10%	22.38%	37.34%	24.58%	26.91%	32.07%	27.17%	29.63%	42.09%
Debt-free Net Working Capital to Revenue	47.60%	49.66%	56.41%	55.67%	71.61%	37.68%	36.34%	46.79%	37.45%	35.54%	51.09%
Net Working Capital to Revenue	9.91%	48.72%	53.96%	52.75%	60.95%	34.72%	34.81%	39.83%	37.45%	33.91%	50.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.09)	$0.85	$2.18	$2.00	$1.58	$0.59	$0.73	$0.84	$1.00	($0.05)	$0.47
Adjusted Weighted Average Basic Shares Outstanding	77.01M	80.09M	83.00M	84.70M	84.65M	85.64M	82.86M	76.90M	74.39M	68.99M	71.72M
Adjusted Diluted Earnings per Share	($0.09)	$0.84	$2.16	$1.98	$1.57	$0.58	$0.72	$0.82	$0.94	($0.05)	$0.47
Adjusted Weighted Average Diluted Shares Outstanding	77.01M	80.34M	83.52M	85.49M	85.23M	86.49M	84.00M	79.12M	79.19M	71.35M	72.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.22M	78.22M	81.64M	83.24M	84.37M	84.44M	85.23M	78.49M	74.82M	74.00M	72.48M
Normalized Net Operating Profit after Tax (NOPAT)	20	93	202	155	106	78	78	31	95	56	54
Normalized NOPAT Margin	1.23%	6.05%	12.95%	10.07%	7.72%	5.16%	5.28%	2.64%	9.59%	6.31%	6.78%
Pre Tax Income Margin	-1.13%	5.26%	13.73%	13.92%	6.82%	3.96%	3.90%	0.96%	9.11%	6.87%	5.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.46	2.24	5.07	5.13	2.18	1.91	1.84	1.32	4.50	3.58	3.07
NOPAT to Interest Expense	0.28	1.81	4.07	3.08	3.03	1.45	1.82	7.28	3.69	0.38	2.46
EBIT Less CapEx to Interest Expense	-1.02	0.94	4.44	4.17	1.68	0.63	0.65	0.08	2.68	2.22	1.32
NOPAT Less CapEx to Interest Expense	-1.20	0.51	3.44	2.13	2.54	0.16	0.62	6.04	1.86	-0.98	0.72
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-755.63%	405.96%	69.23%	0.00%	74.69%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.74%	11.49%	-0.42%	9.68%	-3.14%	-0.25%	-0.72%	-4.16%	1.12%	-1.85%	-0.43%
EBITDA Growth	-35.07%	7.30%	-47.06%	-17.83%	-50.12%	-31.57%	-40.70%	-52.11%	-12.63%	10.48%	6.99%
EBIT Growth	-566.34%	-3.75%	-122.31%	-112.89%	-91.12%	-46.99%	-60.40%	-80.03%	-23.84%	14.92%	11.68%
NOPAT Growth	-490.94%	23.98%	-120.48%	-115.50%	-90.63%	-55.71%	-49.55%	-73.68%	-23.38%	9.64%	14.96%
Net Income Growth	-670.89%	-2.02%	-154.85%	-396.41%	-113.54%	-62.54%	-60.94%	-90.66%	-26.37%	16.66%	15.47%
EPS Growth	-725.00%	-3.85%	-158.33%	-420.00%	-113.79%	-58.73%	-60.00%	-90.74%	-25.64%	18.87%	17.65%
Operating Cash Flow Growth	-171.45%	-13.63%	-16.01%	42.87%	-39.76%	-31.15%	-60.81%	-57.46%	-41.02%	23.18%	-17.48%
Free Cash Flow Firm Growth	-5,159.43%	-1,047.17%	60.07%	-47.53%	103.36%	133.15%	-4,040.08%	-2,266.04%	-171.52%	72.51%	101.80%
Invested Capital Growth	9.95%	10.07%	2.42%	9.10%	-0.11%	-0.11%	8.08%	7.16%	7.59%	5.01%	1.86%
Revenue Q/Q Growth	-13.55%	16.23%	-8.93%	13.37%	-7.09%	3.82%	0.30%	0.11%	-4.32%	3.33%	-3.17%
EBITDA Q/Q Growth	-69.67%	141.92%	-14.70%	3.76%	-49.89%	19.38%	32.38%	-37.01%	-31.25%	3.45%	6.91%
EBIT Q/Q Growth	-142.70%	706.67%	-279.27%	-147.47%	-91.19%	40.63%	119.16%	-67.31%	-47.39%	5.05%	10.50%
NOPAT Q/Q Growth	-135.32%	638.42%	-169.07%	-176.41%	-88.80%	-11.08%	103.65%	-53.78%	-47.09%	1.30%	6.22%
Net Income Q/Q Growth	-230.15%	281.71%	13.76%	-277.99%	-116.54%	1.73%	365.99%	-82.73%	-54.24%	6.07%	11.45%
EPS Q/Q Growth	-232.00%	278.57%	12.50%	-300.00%	-115.38%	8.33%	380.00%	-82.76%	-53.97%	5.00%	11.11%
Operating Cash Flow Q/Q Growth	-122.19%	125.66%	-44.35%	156.42%	-73.18%	119.46%	-5.34%	8.12%	-69.35%	24.92%	2.76%
Free Cash Flow Firm Q/Q Growth	-14.93%	-241.77%	71.37%	-4,598.95%	-78.48%	114.41%	-5.77%	-2.56%	-112.08%	-1,812.72%	-41.85%
Invested Capital Q/Q Growth	0.43%	6.27%	-5.62%	9.16%	0.53%	-1.12%	0.54%	-0.06%	0.53%	6.99%	-0.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	50.81%	56.27%	52.58%	54.02%	56.07%	57.05%	57.10%	54.30%	61.15%	62.83%	61.46%
EBITDA Margin	5.99%	17.08%	8.21%	8.76%	9.57%	17.75%	15.44%	11.70%	18.59%	25.88%	25.85%
Operating Margin	-4.05%	8.05%	-2.14%	-0.72%	1.07%	9.08%	6.95%	3.28%	9.55%	17.04%	16.89%
EBIT Margin	-4.09%	8.28%	-1.59%	-0.38%	0.91%	9.59%	7.08%	3.24%	9.92%	18.04%	17.74%
Profit (Net Income) Margin	-6.61%	4.39%	-2.81%	-2.97%	-0.89%	5.00%	5.10%	1.10%	6.36%	13.30%	12.96%
Tax Burden Percent	84.21%	86.22%	52.52%	81.67%	62.73%	68.73%	104.77%	109.41%	81.36%	82.46%	84.90%
Interest Burden Percent	192.03%	61.53%	337.23%	953.83%	-155.93%	75.82%	68.76%	30.97%	78.84%	89.44%	86.03%
Effective Tax Rate	0.00%	13.78%	0.00%	0.00%	0.00%	31.27%	-4.77%	-9.41%	18.64%	17.54%	15.10%
Return on Invested Capital (ROIC)	-1.48%	3.61%	-0.78%	-0.26%	0.39%	3.26%	3.92%	1.94%	4.24%	7.61%	8.22%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.42%	2.87%	-1.12%	-0.95%	-0.07%	2.87%	3.23%	1.14%	3.80%	7.34%	7.71%
Return on Net Nonoperating Assets (RNNOA)	-2.39%	2.80%	-1.06%	-0.88%	-0.06%	2.12%	2.38%	0.81%	2.81%	4.77%	4.84%
Return on Equity (ROE)	-3.88%	6.41%	-1.83%	-1.13%	0.33%	5.38%	6.30%	2.75%	7.05%	12.38%	13.06%
Cash Return on Invested Capital (CROIC)	-9.28%	-8.94%	-1.72%	-6.91%	2.44%	3.27%	-3.43%	-1.59%	-0.58%	2.12%	5.37%
Operating Return on Assets (OROA)	-1.63%	3.41%	-0.64%	-0.15%	0.36%	3.85%	2.89%	1.33%	4.18%	7.32%	7.33%
Return on Assets (ROA)	-2.64%	1.81%	-1.13%	-1.18%	-0.35%	2.01%	2.08%	0.45%	2.68%	5.40%	5.35%
Return on Common Equity (ROCE)	-3.88%	6.41%	-1.83%	-1.13%	0.33%	5.38%	6.30%	2.75%	7.05%	12.38%	13.06%
Return on Equity Simple (ROE_SIMPLE)	-1.90%	0.00%	-0.43%	1.54%	2.52%	0.00%	6.39%	7.80%	10.26%	0.00%	10.03%
Net Operating Profit after Tax (NOPAT)	-11	31	-5.71	-2.12	2.77	25	28	14	30	56	55
NOPAT Margin	-2.83%	6.94%	-1.50%	-0.51%	0.75%	6.24%	7.29%	3.59%	7.77%	14.05%	14.34%
Net Nonoperating Expense Percent (NNEP)	0.93%	0.74%	0.34%	0.69%	0.46%	0.40%	0.69%	0.80%	0.44%	0.26%	0.50%
Return On Investment Capital (ROIC_SIMPLE)	-0.31%	0.87%	-0.17%	-0.06%	0.08%	0.76%	0.86%	0.42%	0.90%	1.64%	1.69%
Cost of Revenue to Revenue	49.19%	43.73%	47.42%	45.98%	43.93%	42.95%	42.90%	45.70%	38.85%	37.17%	38.54%
SG&A Expenses to Revenue	47.43%	40.33%	46.53%	46.74%	44.95%	41.09%	42.35%	43.25%	43.76%	38.17%	37.34%
R&D to Revenue	6.46%	7.05%	7.20%	7.12%	7.31%	6.12%	6.95%	6.97%	7.02%	6.73%	6.42%
Operating Expenses to Revenue	54.86%	48.22%	54.72%	54.75%	55.00%	47.97%	50.14%	51.02%	51.59%	45.79%	44.57%
Earnings before Interest and Taxes (EBIT)	-16	37	-6.04	-1.59	3.35	38	27	12	38	72	68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	23	76	31	37	35	70	59	45	71	103	100
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.11	1.13	0.93	1.50	1.73	2.14	1.97	2.00	2.80	2.60	2.05
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.05	1.09	0.90	1.47	1.81	2.21	2.02	2.18	3.00	3.01	2.26
Price to Earnings (P/E)	0.00	0.00	0.00	97.10	68.88	50.26	30.83	25.66	27.27	25.94	20.45
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	1.03%	1.45%	1.99%	3.24%	3.90%	3.67%	3.86%	4.89%
Enterprise Value to Invested Capital (EV/IC)	1.05	1.06	0.96	1.24	1.40	1.62	1.51	1.57	2.02	1.98	1.66
Enterprise Value to Revenue (EV/Rev)	2.11	2.14	1.88	2.55	2.70	3.09	2.92	3.01	3.83	3.74	2.92
Enterprise Value to EBITDA (EV/EBITDA)	20.60	19.27	16.92	19.82	19.74	19.44	16.25	14.62	16.31	15.47	12.63
Enterprise Value to EBIT (EV/EBIT)	256.70	106.52	86.98	59.72	51.15	41.32	30.26	24.43	24.93	23.16	18.86
Enterprise Value to NOPAT (EV/NOPAT)	547.41	173.30	145.61	71.87	59.83	51.10	36.31	30.51	31.01	28.89	23.21
Enterprise Value to Operating Cash Flow (EV/OCF)	33.50	26.64	21.39	28.19	31.91	34.02	27.07	22.34	24.26	22.03	18.39
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	57.13	49.36	0.00	0.00	0.00	95.42	31.16
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.32	1.27	1.19	1.30	1.27	1.05	1.06	0.94	0.95	0.89	0.90
Long-Term Debt to Equity	0.91	0.88	0.79	1.28	1.26	1.04	1.01	0.89	0.95	0.87	0.86
Financial Leverage	0.99	0.97	0.94	0.93	0.81	0.74	0.74	0.71	0.74	0.65	0.63
Leverage Ratio	2.60	2.50	2.52	2.44	2.39	2.26	2.28	2.25	2.25	2.20	2.26
Compound Leverage Factor	5.00	1.54	8.49	23.28	-3.73	1.71	1.57	0.70	1.78	1.97	1.94
Debt to Total Capital	56.81%	56.04%	54.28%	56.53%	55.91%	51.21%	51.44%	48.55%	48.80%	47.01%	47.23%
Short-Term Debt to Total Capital	17.36%	17.27%	18.07%	0.69%	0.53%	0.45%	2.63%	2.92%	0.00%	1.12%	1.72%
Long-Term Debt to Total Capital	39.45%	38.77%	36.21%	55.84%	55.37%	50.76%	48.82%	45.63%	48.80%	45.89%	45.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	43.19%	43.96%	45.72%	43.47%	44.09%	48.79%	48.56%	51.45%	51.20%	52.99%	52.77%
Debt to EBITDA	12.04	11.02	10.40	9.90	9.67	6.80	6.03	5.00	4.36	4.25	4.27
Net Debt to EBITDA	10.40	9.49	8.80	8.43	6.51	5.54	5.04	4.02	3.52	3.04	2.85
Long-Term Debt to EBITDA	8.36	7.62	6.94	9.78	9.58	6.74	5.72	4.70	4.36	4.15	4.11
Debt to NOPAT	319.99	99.06	89.51	35.89	29.32	17.88	13.48	10.43	8.28	7.94	7.84
Net Debt to NOPAT	276.37	85.30	75.76	30.55	19.72	14.56	11.27	8.40	6.69	5.67	5.24
Long-Term Debt to NOPAT	222.21	68.53	59.71	35.46	29.04	17.73	12.79	9.80	8.28	7.75	7.55
Altman Z-Score	1.16	1.22	1.08	1.48	1.70	1.96	1.86	1.94	2.39	2.38	2.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.21	1.17	1.20	3.39	4.68	3.45	2.89	2.78	3.65	3.62	3.93
Quick Ratio	0.57	0.59	0.58	1.73	2.99	1.85	1.49	1.50	1.99	2.24	2.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-306	-266	-78	-272	6.04	28	-195	-184	-180	-85	4.94
Operating Cash Flow to CapEx	-38.92%	171.42%	75.85%	136.00%	101.88%	239.45%	204.69%	181.88%	190.86%	590.30%	746.18%
Free Cash Flow to Firm to Interest Expense	-16.24	-14.00	-4.02	-14.57	0.44	2.04	-14.91	-14.77	-14.84	-6.57	0.39
Operating Cash Flow to Interest Expense	-0.60	2.67	1.16	2.17	1.16	4.27	2.05	2.27	2.16	6.62	5.33
Operating Cash Flow Less CapEx to Interest Expense	-2.14	1.11	-0.37	0.57	0.02	2.49	1.05	1.02	1.03	5.50	4.62
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.41	0.40	0.40	0.39	0.40	0.41	0.41	0.42	0.41	0.41
Accounts Receivable Turnover	6.58	6.06	6.20	5.91	6.18	5.90	6.11	6.23	6.40	6.29	6.65
Inventory Turnover	1.78	1.78	1.76	1.78	1.78	1.84	1.87	1.83	1.75	1.83	1.87
Fixed Asset Turnover	4.23	4.32	4.41	4.53	4.63	4.73	4.98	4.99	5.00	5.00	5.26
Accounts Payable Turnover	8.13	8.33	8.24	6.65	6.48	6.76	7.28	7.31	5.89	7.17	8.49
Days Sales Outstanding (DSO)	55.45	60.25	58.84	61.72	59.07	61.89	59.69	58.58	57.02	58.03	54.86
Days Inventory Outstanding (DIO)	205.28	205.11	207.79	205.59	205.29	198.44	194.90	198.99	209.14	199.47	195.54
Days Payable Outstanding (DPO)	44.91	43.80	44.29	54.90	56.36	54.02	50.15	49.94	61.93	50.94	42.99
Cash Conversion Cycle (CCC)	215.82	221.56	222.33	212.41	208.01	206.31	204.44	207.64	204.23	206.56	207.41
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,256	3,242	3,051	3,232	2,961	2,945	2,979	2,963	2,964	2,948	2,756
Invested Capital Turnover	0.52	0.52	0.52	0.51	0.52	0.52	0.54	0.54	0.55	0.54	0.57
Increase / (Decrease) in Invested Capital	295	297	72	270	-3.26	-3.29	223	198	209	141	50
Enterprise Value (EV)	3,430	3,447	2,939	3,994	4,134	4,762	4,508	4,648	5,976	5,827	4,569
Market Capitalization	1,698	1,750	1,410	2,296	2,771	3,405	3,109	3,369	4,687	4,683	3,537
Book Value per Share	$19.74	$20.03	$19.61	$19.47	$20.56	$20.31	$19.40	$20.55	$20.52	$21.60	$20.65
Tangible Book Value per Share	($9.96)	($9.84)	($10.37)	($10.03)	($5.98)	($6.85)	($6.44)	($5.54)	($5.82)	($4.32)	($3.68)
Total Capital	3,529	3,515	3,328	3,529	3,624	3,254	3,252	3,272	3,272	3,405	3,268
Total Debt	2,005	1,970	1,807	1,995	2,026	1,666	1,673	1,589	1,597	1,601	1,543
Total Long-Term Debt	1,392	1,363	1,205	1,971	2,007	1,652	1,588	1,493	1,597	1,563	1,487
Net Debt	1,731	1,696	1,529	1,698	1,363	1,357	1,399	1,279	1,289	1,144	1,031
Capital Expenditures (CapEx)	29	30	30	30	15	25	13	16	14	14	9.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	528	493	511	511	470	456	483	460	440	422	436
Debt-free Net Working Capital (DFNWC)	801	767	788	808	1,133	766	757	769	747	879	948
Net Working Capital (NWC)	189	160	187	784	1,113	751	672	674	747	841	892
Net Nonoperating Expense (NNE)	14	11	4.99	10	6.06	4.94	8.36	9.50	5.37	2.99	5.31
Net Nonoperating Obligations (NNO)	1,731	1,696	1,529	1,698	1,363	1,357	1,399	1,279	1,289	1,144	1,031
Total Depreciation and Amortization (D&A)	39	39	37	38	32	32	32	32	33	31	31
Debt-free, Cash-free Net Working Capital to Revenue	32.52%	30.62%	32.64%	32.64%	30.70%	29.61%	31.32%	29.78%	28.16%	27.10%	27.88%
Debt-free Net Working Capital to Revenue	49.34%	47.60%	50.38%	51.59%	74.05%	49.66%	49.07%	49.79%	47.84%	56.41%	60.58%
Net Working Capital to Revenue	11.62%	9.91%	11.95%	50.05%	72.78%	48.72%	43.53%	43.60%	47.84%	53.96%	56.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.33)	$0.25	($0.14)	($0.16)	($0.04)	$0.26	$0.24	$0.05	$0.30	$0.65	$0.60
Adjusted Weighted Average Basic Shares Outstanding	76.46M	77.01M	76.45M	77.41M	77.74M	80.09M	79.69M	80.97M	81.87M	83.00M	83.04M
Adjusted Diluted Earnings per Share	($0.33)	$0.25	($0.14)	($0.16)	($0.04)	$0.26	$0.24	$0.05	$0.29	$0.63	$0.60
Adjusted Weighted Average Diluted Shares Outstanding	76.46M	77.01M	76.45M	77.41M	77.74M	80.34M	79.81M	81.15M	82.32M	83.52M	83.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.71M	77.22M	77.16M	77.58M	78.80M	78.22M	78.18M	81.40M	81.90M	81.64M	83.52M
Normalized Net Operating Profit after Tax (NOPAT)	-11	31	-5.71	-2.12	2.77	25	19	8.75	30	56	55
Normalized NOPAT Margin	-2.83%	6.94%	-1.50%	-0.51%	0.75%	6.24%	4.87%	2.30%	7.77%	14.05%	14.34%
Pre Tax Income Margin	-7.85%	5.09%	-5.35%	-3.63%	-1.42%	7.27%	4.87%	1.00%	7.82%	16.13%	15.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.83	1.93	-0.31	-0.09	0.25	2.77	2.07	0.99	3.12	5.57	5.34
NOPAT to Interest Expense	-0.58	1.62	-0.29	-0.11	0.20	1.80	2.13	1.10	2.45	4.34	4.31
EBIT Less CapEx to Interest Expense	-2.37	0.37	-1.84	-1.68	-0.89	0.98	1.07	-0.26	1.99	4.45	4.62
NOPAT Less CapEx to Interest Expense	-2.11	0.06	-1.82	-1.71	-0.93	0.02	1.13	-0.15	1.31	3.22	3.60
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-755.63%	-764.06%	740.02%	310.68%	405.96%	272.67%	114.27%	87.27%	69.23%	72.26%

Frequently Asked Questions About Integra LifeSciences' Financials

When does Integra LifeSciences's financial year end?

According to the most recent income statement we have on file, Integra LifeSciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Integra LifeSciences' net income changed over the last 10 years?

Integra LifeSciences' net income appears to be on an upward trend, with a most recent value of -$6.94 million in 2024, falling from $34.00 million in 2014. The previous period was $67.74 million in 2023. See Integra LifeSciences' forecast for analyst expectations on what’s next for the company.

What is Integra LifeSciences's operating income?

Integra LifeSciences's total operating income in 2024 was $28.41 million, based on the following breakdown:

Total Gross Profit: $882.06 million
Total Operating Expenses: $853.65 million

How has Integra LifeSciences revenue changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' total revenue changed from $796.72 million in 2014 to $1.61 billion in 2024, a change of 102.1%.

How much debt does Integra LifeSciences have?

Integra LifeSciences' total liabilities were at $2.49 billion at the end of 2024, a 13.6% increase from 2023, and a 182.2% increase since 2014.

How much cash does Integra LifeSciences have?

In the past 10 years, Integra LifeSciences' cash and equivalents has ranged from $48.13 million in 2015 to $513.45 million in 2021, and is currently $246.38 million as of their latest financial filing in 2024.

How has Integra LifeSciences' book value per share changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' book value per share changed from 21.48 in 2014 to 20.03 in 2024, a change of -6.8%.

Related Companies

This page (NASDAQ:IART) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integra LifeSciences (IART) Financials

Frequently Asked Questions About Integra LifeSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Integra LifeSciences (IART) Financials

Annual Income Statements for Integra LifeSciences

Quarterly Income Statements for Integra LifeSciences

Annual Cash Flow Statements for Integra LifeSciences

Quarterly Cash Flow Statements for Integra LifeSciences

Annual Balance Sheets for Integra LifeSciences

Quarterly Balance Sheets for Integra LifeSciences

Annual Metrics And Ratios for Integra LifeSciences

Quarterly Metrics And Ratios for Integra LifeSciences

Frequently Asked Questions About Integra LifeSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools